Neurol. praxi. 2022;23(3):227-230 | DOI: 10.36290/neu.2022.031

Elimination half‑life is not just a pharmacological profile

MUDr. Ondřej Strýček, Ph.D.1, 2, MUDr. Jitka Kočvarová1
1 Centrum pro epilepsie Brno, I. neurologická klinika FN u sv. Anny a Lékařské fakulty Masarykovy univerzity, Brno
2 Středoevropský technologický institut - CEITEC, Brno

When choosing the optimal drug, we focus on several key characteristics of the drug. The drug pharmacokinetic profile is usually a less significant factor in this choice. The aim of the following article is to clearly explain why we should pay particular attention to the elimination half-life as an important pharmacokinetic parameter. We also want to point out its role in anti-seizure medication, for which the stability of plasma drug levels is essential.

Keywords: elimination half­‑life, anti­‑seizure medication, epilepsy.

Received: May 20, 2022; Revised: May 20, 2022; Accepted: May 23, 2022; Prepublished online: May 23, 2022; Published: June 16, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Strýček O, Kočvarová J. Elimination half‑life is not just a pharmacological profile. Neurol. praxi. 2022;23(3):227-230. doi: 10.36290/neu.2022.031.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Aícua­‑Rapún I, André P, Rossetti AO, et al. Therapeutic Drug Monitoring of Newer Antiepileptic Drugs: A Randomized Trial for Dosage Adjustment. Ann Neurol. 2020;87(1): 22-29. doi: 10.1002/ana.25641. Go to original source... Go to PubMed...
    2. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296-310. doi: 10.1016/s0149-2918(01)80109-0. Go to original source... Go to PubMed...
    3. Cramer JA, Glassman M, Rienzi V. The relationship between poor medication compliance and seizures. Epilepsy Behav. 2002;3(4):338-342. doi: 10.1016/s1525-5050(02)00037-9. Go to original source... Go to PubMed...
    4. Dooley JM, Camfield PR, Camfield CS, et al. Once­‑daily ethosuximide in the treatment of absence epilepsy. Pediatr Neurol. 1990;6(1):38-9. doi: 10.1016/0887-8994(90)90076-d. Go to original source... Go to PubMed...
    5. Gidal BE, Ferry J, Reyderman L, et al. Use of extended­‑release and immediate­‑release anti­‑seizure medications with a long half­‑life to improve adherence in epilepsy: a guide for clinicians. Epilepsy Behav. 2021;120:107993. doi: 10.1016/j.yebeh.2021.107993 Go to original source... Go to PubMed...
    6. Kim SH, Lee H, Kim DW. Switching antiepileptic drugs to once­‑daily dosing regimens in epilepsy patients. Acta Neurol Scand. 2021 Jan;143(1):51-55. doi: 10.1111/ane.13333. Go to original source... Go to PubMed...
    7. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314-9. doi: 10.1056/NEJM200002033420503. Go to original source... Go to PubMed...
    8. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. 2000;85(2):77-85. doi: 10.1016/s0163-7258(99)00052-2. Go to original source... Go to PubMed...
    9. Patsalos PN, St Louis EK. The Epilepsy Prescriber's Guide to Antiepileptic Drugs - third Edition. Cambridge University Press. 2018;19-249. doi: 10.1017/9781108669399. Go to original source...
    10. Southwood RL, Fleming VH, Huckaby G. Concepts in clinical pharmacokinetics. 7th ed. Bethesda: American Society of Health­‑System Pharmacists; 2018; 53-56 s. ISBN 9781585285914
    11. Steinhoff BJ, Hübers E, Kurth C, et al. Plasma concentration and clinical effects of perampanel­‑The Kork experience. Seizure. 2019;67:18-22. doi: 10.1016/j.seizure.2019. 02. 022. Go to original source...
    12. Tompson DJ, Ali I, Oliver­‑Willwong, et al. Steady­‑state pharmacokinetics of lamotrigine when converting from a twice­‑daily immediate­‑release to a once­‑daily extended­‑release formulation in subjects with epilepsy (The COMPASS Study). Epilepsia. 2008;49(3):410-7. doi: 10.1111/j.1528-1167.2007.01274.x. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.